[{"symbol": "VRTX", "publishedDate": "2020-09-28 12:35:00", "title": "Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants", "image": "https://cdn.snapi.dev/images/v1/2/s/biotech18.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) wins an FDA approval for Kalydeco to treat cystic fibrosis in infants aged four to less than six months with minimum one mutation in their CFTR gene that is responsive to Kalydeco.", "url": "https://www.zacks.com/stock/news/1068151/vertexs-kalydeco-gets-fda-nod-for-cystic-fibrosis-in-infants"}, {"symbol": "VRTX", "publishedDate": "2020-09-28 07:19:29", "title": "5 Jefferies High-Conviction Health Care Stocks May Be Huge Q4 Winners", "image": "https://cdn.snapi.dev/images/v1/w/t/stocks8-71.jpg", "site": "24/7 Wall Street", "text": "With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at what should be an improving 2021 economy as we emerge from the COVID-19 pandemic restrictions.", "url": "https://247wallst.com/healthcare-business/2020/09/28/5-jefferies-high-conviction-health-care-stocks-may-be-huge-q4-winners/"}, {"symbol": "VRTX", "publishedDate": "2020-09-25 09:54:16", "title": "Biotech Short Sellers Hike Their Bets", "image": "https://cdn.snapi.dev/images/v1/j/e/biotech30.jpg", "site": "24/7 Wall Street", "text": "The short interest data are out for September 15, the most recent settlement date.", "url": "https://247wallst.com/healthcare-business/2020/09/25/biotech-short-sellers-hike-their-bets/"}, {"symbol": "VRTX", "publishedDate": "2020-09-25 08:00:00", "title": "FDA Approves KALYDECO\u00ae (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age", "image": "https://cdn.snapi.dev/images/v1/h/4/press6-4.jpg", "site": "Business Wire", "text": "BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO\u00ae (ivacaftor) for use in children with cystic fibrosis (CF) ages four months to less than six months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO based on clinical and/or in vitro assay data. KALYDECO is already approved in the U.S. and EU for the trea", "url": "https://www.businesswire.com/news/home/20200925005076/en/FDA-Approves-KALYDECO%C2%AE-ivacaftor-as-First-and-Only-CFTR-Modulator-to-Treat-Eligible-Infants-With-CF-as-Early-as-Four-Months-of-Age/"}, {"symbol": "VRTX", "publishedDate": "2020-09-24 05:25:00", "title": "Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators", "image": "https://cdn.snapi.dev/images/v1/0/x/press16-2.jpg", "site": "Business Wire", "text": "BOSTON--(BUSINESS WIRE)-- #ECFS2020--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company\u2019s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA", "url": "https://www.businesswire.com/news/home/20200924005175/en/Vertex-to-Present-New-Data-at-European-and-North-American-Virtual-Cystic-Fibrosis-Conferences-Highlighting-Long-Term-Use-of-CFTR-Modulators/"}, {"symbol": "VRTX", "publishedDate": "2020-09-23 07:07:00", "title": "Stock Market Crash 2.0: Where to Invest $1,000", "image": "https://cdn.snapi.dev/images/v1/t/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5923232fgettyimages-864893078jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Buying and holding these growth stocks would be the best way to endure the market mayhem.", "url": "https://www.fool.com/investing/2020/09/23/stock-market-crash-20-where-to-invest-1000/"}, {"symbol": "VRTX", "publishedDate": "2020-09-21 17:50:14", "title": "Vertex Pharmaceuticals (VRTX) Stock Moves -0.52%: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/q/a/biotech30.jpg", "site": "Zacks Investment Research", "text": "Vertex Pharmaceuticals (VRTX) closed at $264 in the latest trading session, marking a -0.52% move from the prior day.", "url": "https://www.zacks.com/stock/news/1061322/vertex-pharmaceuticals-vrtx-stock-moves-052-what-you-should-know"}, {"symbol": "VRTX", "publishedDate": "2020-09-17 20:03:00", "title": "Beyond Coronavirus: Moderna Teams Up With Vertex on Cystic Fibrosis Therapy", "image": "https://cdn.snapi.dev/images/v1/f/n/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5921572fdoctor-patient-stethoscopejpgw700opresize.jpg", "site": "The Motley Fool", "text": "This is the companies' second project to tackle the lung disease.", "url": "https://www.fool.com/investing/2020/09/17/beyond-coronavirus-moderna-teams-up-with-vertex-on/"}, {"symbol": "VRTX", "publishedDate": "2020-09-17 06:16:00", "title": "Stock Market Crash 2.0: Here Are 3 Stocks You'll Absolutely, Positively Want to Buy", "image": "https://cdn.snapi.dev/images/v1/k/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5308742fgettyimages-1003599708jpgw700opresize.jpg", "site": "The Motley Fool", "text": "These stocks are great candidates to buy on the dip -- especially if that dip is a big one.", "url": "https://www.fool.com/investing/2020/09/17/stock-market-crash-20-here-are-3-stocks-youll-abso/"}, {"symbol": "VRTX", "publishedDate": "2020-09-16 16:33:54", "title": "3 Nasdaq Stocks to Buy Off Their Corrective Bottoms", "image": "https://cdn.snapi.dev/images/v1/0/v/ees23-9.jpg", "site": "InvestorPlace", "text": "The best Nasdaq stocks to buy aren\u2019t those with the biggest capitalization gains, but those whose shares have put in the work on the price chart.\r\nThe post 3 Nasdaq Stocks to Buy Off Their Corrective Bottoms appeared first on InvestorPlace.", "url": "https://investorplace.com/2020/09/3-nasdaq-stocks-to-buy-off-their-corrective-bottoms/"}, {"symbol": "VRTX", "publishedDate": "2020-09-16 16:30:00", "title": "Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing", "image": "https://cdn.snapi.dev/images/v1/t/y/press18-7.jpg", "site": "Business Wire", "text": "CAMBRIDGE & BOSTON, Mass.--(BUSINESS WIRE)--Moderna and Vertex establish new collaboration to treat cystic fibrosis using gene editing.", "url": "https://www.businesswire.com/news/home/20200916005915/en/Moderna-and-Vertex-Establish-New-Collaboration-to-Treat-Cystic-Fibrosis-Using-Gene-Editing/"}, {"symbol": "VRTX", "publishedDate": "2020-09-15 10:13:00", "title": "Vertex Eyes Label Expansion of Triple Combo CF Drug in Europe", "image": "https://cdn.snapi.dev/images/v1/x/p/biotech32.jpg", "site": "Zacks Investment Research", "text": "Vertex's (VRTX) label expansion application Kaftrio in combination with Kalydeco gets accepted for review by the European Medicines Agency.", "url": "https://www.zacks.com/stock/news/1058583/vertex-eyes-label-expansion-of-triple-combo-cf-drug-in-europe"}, {"symbol": "VRTX", "publishedDate": "2020-09-14 04:15:00", "title": "\u00a0Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation", "image": "https://cdn.snapi.dev/images/v1/c/c/press1-2.jpg", "site": "Business Wire", "text": "LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO\u00ae* (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If approved, eligible", "url": "https://www.businesswire.com/news/home/20200914005342/en/%C2%A0Vertex-Announces-European-Medicines-Agency-Type-II-Variation-Marketing-Authorization-Application-Validation-for-KAFTRIO%C2%AE-ivacaftortezacaftorelexacaftor-in-Combination-with-ivacaftor-in-People-with-One-Copy-of-the-F508del-Mutation/"}, {"symbol": "VRTX", "publishedDate": "2020-09-13 06:52:00", "title": "Got $5,000? 3 Surefire Stocks to Buy Ahead of the Next Market Crash", "image": "https://cdn.snapi.dev/images/v1/w/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5614122f3-test-tubesjpgw700opresize.jpg", "site": "The Motley Fool", "text": "The long-term picture is bright for these healthcare stocks thanks to stable product revenue.", "url": "https://www.fool.com/investing/2020/09/13/got-5000-3-surefire-stocks-to-buy-ahead-of-the-nex/"}, {"symbol": "VRTX", "publishedDate": "2020-09-11 10:05:24", "title": "Short Sellers Hike Their Bets in Major Biotechs", "image": "https://cdn.snapi.dev/images/v1/o/o/biotech22-3.jpg", "site": "24/7 Wall Street", "text": "The short interest data are out for August 31, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.", "url": "https://247wallst.com/healthcare-business/2020/09/11/short-sellers-hike-their-bets-in-major-biotechs-3/"}, {"symbol": "VRTX", "publishedDate": "2020-09-11 06:08:00", "title": "3 Incredibly Strong Stocks to Buy That Should Thrive Even If the Stock Market Crashes Again", "image": "https://cdn.snapi.dev/images/v1/x/c/etf35-33.jpg", "site": "The Motley Fool", "text": "These rock-solid businesses should be resilient no matter what happens with the stock market or the economy.", "url": "https://www.fool.com/investing/2020/09/11/3-incredibly-strong-stocks-to-buy-that-should-thri/"}, {"symbol": "VRTX", "publishedDate": "2020-09-10 15:32:00", "title": "Vertex Pharmaceuticals Reports Positive Phase 3 Results in Children for Blockbuster CF Drug", "image": "https://cdn.snapi.dev/images/v1/u/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5913132fgettyimages-1190193669jpgw700opresize.jpg", "site": "The Motley Fool", "text": "The cystic fibrosis treatment specialist says it will submit a supplemental New Drug Application for Trikafta this year.", "url": "https://www.fool.com/investing/2020/09/10/vertex-pharmaceuticals-reports-positive-phase-3-re/"}, {"symbol": "VRTX", "publishedDate": "2020-09-10 09:00:00", "title": "Vertex Announces Positive Phase 3 Study for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals", "image": "https://cdn.snapi.dev/images/v1/n/w/press8-2.jpg", "site": "Business Wire", "text": "BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company has completed a global Phase 3 study of TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children ages 6 through 11 years old with cystic fibrosis (CF) who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation, and based on the results will submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Ad", "url": "https://www.businesswire.com/news/home/20200910005580/en/Vertex-Announces-Positive-Phase-3-Study-TRIKAFTA%C2%AE/"}, {"symbol": "VRTX", "publishedDate": "2020-09-09 17:26:00", "title": "CRISPR Stocks: Buy or Trade?", "image": "https://cdn.snapi.dev/images/v1/r/z/etf14.jpg", "site": "Zacks Investment Research", "text": "Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?", "url": "https://www.zacks.com/stock/news/1056009/crispr-stocks-buy-or-trade"}, {"symbol": "VRTX", "publishedDate": "2020-09-09 07:15:00", "title": "Could Vertex Pharmaceuticals Be a Millionaire-Maker Stock?", "image": "https://cdn.snapi.dev/images/v1/g/o/5036jpgwidth460quality85autoformatfitmaxsf7c6b95f0aa1891b02665c830f2dc0d7-2.jpg", "site": "The Motley Fool", "text": "The pharma giant controls a massive addressable market and has proven its ability to increase drug sales.", "url": "https://www.fool.com/investing/2020/09/09/could-vertex-pharmaceuticals-be-a-millionaire-make/"}, {"symbol": "VRTX", "publishedDate": "2020-09-04 09:15:00", "title": "Next Coronavirus Market Crash: Where to Invest $1,000", "image": "https://cdn.snapi.dev/images/v1/4/e/653.jpg", "site": "The Motley Fool", "text": "These three stocks are among the few winners to emerge from the coronavirus stock market.", "url": "https://www.fool.com/investing/2020/09/04/next-coronavirus-market-crash-where-to-invest-1000/"}, {"symbol": "VRTX", "publishedDate": "2020-09-04 06:11:00", "title": "Got $3,000? Buying These 3 Stocks Could Make You Rich", "image": "https://cdn.snapi.dev/images/v1/m/o/gettyimages-1047349788-1jpgw588-5.jpg", "site": "The Motley Fool", "text": "All you have to do is buy -- and wait.", "url": "https://www.fool.com/investing/2020/09/04/got-3000-buying-these-3-stocks-could-make-you-rich/"}, {"symbol": "VRTX", "publishedDate": "2020-09-02 10:49:00", "title": "Vertex Seeks Nod for Cystic Fibrosis Drugs for Rare Mutations", "image": "https://cdn.snapi.dev/images/v1/x/8/biotech1.jpg", "site": "Zacks Investment Research", "text": "Vertex's (VRTX) sNDAs seek approval of Trikafta, Symdeko, and Kalydeco for additional rare mutations in the CFTR genes.", "url": "https://www.zacks.com/stock/news/1051795/vertex-seeks-nod-for-cystic-fibrosis-drugs-for-rare-mutations"}, {"symbol": "VRTX", "publishedDate": "2020-09-01 09:00:00", "title": "FDA Accepts Vertex\u2019s Supplemental New Drug Applications for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) and KALYDECO\u00ae (ivacaftor) for Additional CFTR Mutations", "image": "https://cdn.snapi.dev/images/v1/k/q/press13-2.jpg", "site": "Business Wire", "text": "BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted three supplemental New Drug Applications (sNDAs) for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) and KALYDECO\u00ae (ivacaftor).", "url": "https://www.businesswire.com/news/home/20200901005393/en/FDA-Accepts-Vertex%E2%80%99s-Supplemental-New-Drug-Applications/"}, {"symbol": "VRTX", "publishedDate": "2020-08-29 11:32:08", "title": "Why Is Vertex (VRTX) Down 3.4% Since Last Earnings Report?", "image": "https://cdn.snapi.dev/images/v1/e/a/biotech40.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?", "url": "https://www.zacks.com/stock/news/1049514/why-is-vertex-vrtx-down-34-since-last-earnings-report"}, {"symbol": "VRTX", "publishedDate": "2020-08-28 11:30:17", "title": "Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?", "image": "https://cdn.snapi.dev/images/v1/9/u/biotech28.jpg", "site": "Zacks Investment Research", "text": "Is  (VRTX) Outperforming Other Medical Stocks This Year?", "url": "https://www.zacks.com/stock/news/1049108/is-vertex-pharmaceuticals-vrtx-stock-outpacing-its-medical-peers-this-year"}, {"symbol": "VRTX", "publishedDate": "2020-08-28 09:47:00", "title": "Biotech Industry Near-Term Outlook Modest Amid Coronavirus", "image": "https://cdn.snapi.dev/images/v1/d/p/biotech31.jpg", "site": "Zacks Investment Research", "text": "Biotech Industry Near-Term Outlook Modest Amid Coronavirus", "url": "https://www.zacks.com/commentary/1048937/biotech-industry-near-term-outlook-modest-amid-coronavirus"}, {"symbol": "VRTX", "publishedDate": "2020-08-27 06:30:00", "title": "These 10 Stocks Are the Biggest S&P 500 Healthcare Winners of 2020", "image": "https://cdn.snapi.dev/images/v1/h/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5889852fgettyimages-1141977907jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.", "url": "https://www.fool.com/investing/2020/08/27/these-10-healthcare-stocks-are-the-biggest-sp-500/"}, {"symbol": "VRTX", "publishedDate": "2020-08-26 10:13:43", "title": "Major Biotechs Scare Off Short Sellers", "image": "https://cdn.snapi.dev/images/v1/d/n/dna-3656587-1920-1.jpg", "site": "24/7 Wall Street", "text": "The short interest data are out for August 14, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.", "url": "https://247wallst.com/healthcare-business/2020/08/26/major-biotechs-scare-off-short-sellers-5/"}, {"symbol": "VRTX", "publishedDate": "2020-08-24 12:26:00", "title": "Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod", "image": "https://cdn.snapi.dev/images/v1/v/e/vedswq.jpg", "site": "Zacks Investment Research", "text": "Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.", "url": "https://www.zacks.com/stock/news/1046536/vertexs-triple-combo-cystic-fibrosis-pill-kaftrio-gets-eu-nod"}, {"symbol": "VRTX", "publishedDate": "2020-08-21 09:07:00", "title": "European Commission Approves KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older", "image": "https://cdn.snapi.dev/images/v1/q/6/press2-4.jpg", "site": "Business Wire", "text": "LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission (EC) has granted marketing authorization for KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor to treat people with cystic fibrosis (CF) ages 12 years and older with one F508del mutation and one minimal function mutation (F/MF), or two F508del mutations (F/F) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. For the firs", "url": "https://www.businesswire.com/news/home/20200821005298/en/European-Commission-Approves-KAFTRIO%C2%AE-ivacaftortezacaftorelexacaftor-Combination-Ivacaftor/"}, {"symbol": "VRTX", "publishedDate": "2020-08-20 06:08:00", "title": "3 Biotech Stocks You Can Buy and Hold for the Next Decade", "image": "https://cdn.snapi.dev/images/v1/g/t/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5882102f2020-with-ladder-to-2030jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Their approved treatment lineups and pipeline candidates should make them all winners through 2030 at least.", "url": "https://www.fool.com/investing/2020/08/20/3-biotech-stocks-you-can-buy-and-hold-for-the-next/"}, {"symbol": "VRTX", "publishedDate": "2020-08-18 11:45:00", "title": "Stock Upgrades: Vertex Pharmaceuticals Shows Rising Relative Strength", "image": "https://cdn.snapi.dev/images/v1/s/h/biotech14.jpg", "site": "Investors Business Daily", "text": "Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating\nThe post Stock Upgrades: Vertex Pharmaceuticals Shows Rising Relative Strength appeared first on Investor's Business Daily.", "url": "https://www.investors.com/news/technology/stock-upgrades-vertex-pharmaceuticals-shows-rising-relative-strength-3/"}, {"symbol": "VRTX", "publishedDate": "2020-08-13 14:19:25", "title": "5 Disruptive Biotech Stocks to Buy for the Future That Is Here", "image": "https://cdn.snapi.dev/images/v1/a/a/biotech1600-768x432.jpg", "site": "InvestorPlace", "text": "Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.", "url": "https://investorplace.com/2020/08/5-disruptive-biotech-stocks-to-buy-for-the-future-that-is-here/"}, {"symbol": "VRTX", "publishedDate": "2020-08-13 07:38:00", "title": "2 Revolutionary Biotech Stocks to Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/t/s/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5452622fgettyimages-1086688132jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Each of these companies has the potential to generate life-changing returns.", "url": "https://www.fool.com/investing/2020/08/13/2-revolutionary-biotech-stocks-to-buy-right-now/"}, {"symbol": "VRTX", "publishedDate": "2020-08-11 17:13:14", "title": "Top Growth Stocks For August", "image": "https://cdn.snapi.dev/images/v1/4/4/top-growth-stocks-for-august.jpg", "site": "Forbes", "text": "The US-China tensions continue to keep markets at bay, but growth companies continue to be leaders for the market overall. Our deep learning algorithms using  AI technology have rated some of Top Growth Stocks below if you're looking to invest long-term on some future prospects.", "url": "https://www.forbes.com/sites/qai/2020/08/11/top-growth-stocks/"}, {"symbol": "VRTX", "publishedDate": "2020-08-09 12:29:21", "title": "Biotech's Q2:\u00a0 Lots Of Candidates That May Deliver Alpha", "image": "https://cdn.snapi.dev/images/v1/5/0/5036jpgwidth460quality85autoformatfitmaxsf7c6b95f0aa1891b02665c830f2dc0d7-2.jpg", "site": "Seeking Alpha", "text": "The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.", "url": "https://seekingalpha.com/article/4366770-biotechs-q2-lots-of-candidates-may-deliver-alpha?utm_source=feed_articles_stock_ideas_quick_picks&utm_medium=referral"}, {"symbol": "VRTX", "publishedDate": "2020-08-07 08:23:00", "title": "Why Vertex Pharmaceuticals Is the Best Biotech Stock to Buy in August", "image": "https://cdn.snapi.dev/images/v1/v/x/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5852362fgettyimages-845311230jpgw700opresize.jpg", "site": "The Motley Fool", "text": "The momentum is not over for this company or its blockbuster cystic fibrosis drug.", "url": "https://www.fool.com/investing/2020/08/07/why-vertex-pharmaceuticals-is-the-best-biotech-sto.aspx"}, {"symbol": "VRTX", "publishedDate": "2020-08-06 09:14:00", "title": "3 Pharmaceutical Stocks That Can Make You Rich", "image": "https://cdn.snapi.dev/images/v1/a/b/drugs47.jpg", "site": "The Motley Fool", "text": "Some of the most promising stocks on the market right now are pharmaceuticals.", "url": "https://www.fool.com/investing/2020/08/06/3-pharmaceutical-stocks-that-can-make-you-rich.aspx"}, {"symbol": "VRTX", "publishedDate": "2020-08-06 08:08:00", "title": "2 Rock-Solid Pharma Stocks That Won't Flinch if the Market Crashes", "image": "https://cdn.snapi.dev/images/v1/c/z/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5857052fgettyimages-1130771131jpgw700opresize.jpg", "site": "The Motley Fool", "text": "These two stocks weathered the March crash without incident.", "url": "https://www.fool.com/investing/2020/08/06/2-rock-solid-pharma-stocks-that-wont-flinch-if-the.aspx"}, {"symbol": "VRTX", "publishedDate": "2020-07-31 12:33:00", "title": "Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up", "image": "https://cdn.snapi.dev/images/v1/m/i/biotech32.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.", "url": "https://www.zacks.com/stock/news/1029106/vertex-vrtx-q2-earnings-sales-beat-revenue-guidance-up"}, {"symbol": "VRTX", "publishedDate": "2020-07-31 06:42:00", "title": "How Vertex Pharmaceuticals Wowed With Its Q2 Results", "image": "https://cdn.snapi.dev/images/v1/e/l/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5848732fpharmacists-filling-pillsjpgw700opresize.jpg", "site": "The Motley Fool", "text": "There's a one-word answer: Trikafta.", "url": "https://www.fool.com/investing/2020/07/31/how-vertex-pharmaceuticals-wowed-with-its-q2-resul.aspx"}, {"symbol": "VRTX", "publishedDate": "2020-07-30 23:53:05", "title": "Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2020 Results - Earnings Call Transcript", "image": "https://cdn.snapi.dev/images/v1/d/p/transcript45-2.jpg", "site": "Seeking Alpha", "text": "Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2020 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4362716-vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q2-2020-results-earnings-call"}, {"symbol": "VRTX", "publishedDate": "2020-07-30 17:35:08", "title": "Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates", "image": "https://cdn.snapi.dev/images/v1/q/m/biotech38-8.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) delivered earnings and revenue surprises of 22.54% and 8.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?", "url": "https://www.zacks.com/stock/news/1028205/vertex-pharmaceuticals-vrtx-tops-q2-earnings-and-revenue-estimates"}, {"symbol": "VRTX", "publishedDate": "2020-07-30 16:17:15", "title": "Vertex Stock Rises After Second-Quarter Earnings Beat Views", "image": "https://cdn.snapi.dev/images/v1/e/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5284572ffemale-scientist-with-pipette-in-labjpgw700opresize.jpg", "site": "Investors Business Daily", "text": "Vertex Pharmaceuticals late Thursday reported adjusted earnings of $2.61 per share on $1.52 billion in sales for its second quarter, both numbers well above expectations, and shares rose .\r\nThe post Vertex Stock Rises After Second-Quarter Earnings Beat Views appeared first on Investor's Business Daily.", "url": "https://www.investors.com/news/technology/vertex-stock-rises-second-quarter-earnings-beat-views/"}, {"symbol": "VRTX", "publishedDate": "2020-07-30 16:01:00", "title": "Vertex Reports Second-Quarter 2020 Financial Results", "image": "https://cdn.snapi.dev/images/v1/1/x/press15.jpg", "site": "Business Wire", "text": "BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2020 and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues. \"This has been an exceptional first half for Vertex on all fronts and most importantly, in our efforts to bring our CF medicines to more people around the world.", "url": "https://www.businesswire.com/news/home/20200730005957/en/Vertex-Reports-Second-Quarter-2020-Financial-Results/"}, {"symbol": "VRTX", "publishedDate": "2020-07-28 18:38:15", "title": "Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players", "image": "https://cdn.snapi.dev/images/v1/c/3/biotech12.jpg", "site": "Seeking Alpha", "text": "Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players", "url": "https://seekingalpha.com/article/4361562-vertex-pharmaceuticals-67-yoy-returns-4-downside-risk-calling-all-medium-term-players"}, {"symbol": "VRTX", "publishedDate": "2020-07-27 12:26:27", "title": "Vertex Pharmaceuticals For A Strong Portfolio", "image": "https://cdn.snapi.dev/images/v1/v/s/biotech3.jpg", "site": "Seeking Alpha", "text": "Vertex Pharmaceuticals For A Strong Portfolio", "url": "https://seekingalpha.com/article/4361041-vertex-pharmaceuticals-for-strong-portfolio"}, {"symbol": "VRTX", "publishedDate": "2020-07-27 12:10:16", "title": "Why Vertex (VRTX) Could Beat Earnings Estimates Again", "image": "https://cdn.snapi.dev/images/v1/p/3/biotech4.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "url": "https://www.zacks.com/stock/news/1016711/why-vertex-vrtx-could-beat-earnings-estimates-again"}, {"symbol": "VRTX", "publishedDate": "2020-07-25 07:30:00", "title": "3 Unstoppable Stocks to Buy Before the Next Market Crash", "image": "https://cdn.snapi.dev/images/v1/c/r/biotech17.jpg", "site": "The Motley Fool", "text": "The healthcare industry is a good place to shop for stocks to keep your portfolio healthy during the next market crash.", "url": "https://www.fool.com/investing/2020/07/25/3-unstoppable-stocks-to-buy-next-market-crash.aspx"}, {"symbol": "VRTX", "publishedDate": "2020-07-24 19:47:00", "title": "Stocks To Watch With Next Quarterly Report On Tap: Vertex Pharmaceuticals", "image": "https://cdn.snapi.dev/images/v1/a/z/biotech22.jpg", "site": "Investors Business Daily", "text": "IBD 50 and Sector Leaders member Vertex Pharmaceuticals is expected to report earnings on Jul. 30. It's trading now trading 6% below the 295.65 buy point from a second-stage flat.", "url": "https://www.investors.com/news/technology/stocks-to-watch-with-next-quarterly-report-on-tap-vertex-pharmaceuticals/"}, {"symbol": "VRTX", "publishedDate": "2020-07-24 12:45:00", "title": "Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?", "image": "https://cdn.snapi.dev/images/v1/3/o/biotech15.jpg", "site": "Zacks Investment Research", "text": "On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.", "url": "https://www.zacks.com/stock/news/1015618/can-trikafta-drive-vertexs-vrtx-revenues-in-q2-earnings"}, {"symbol": "VRTX", "publishedDate": "2020-07-24 10:51:30", "title": "Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks", "image": "https://cdn.snapi.dev/images/v1/s/c/106298733-1576513139338gettyimages-880891422.jpeg", "site": "24/7 Wall Street", "text": "The health care sector has been a big winner in 2020, far outpacing the Dow Jones industrial average and S&P 500.", "url": "https://247wallst.com/healthcare-business/2020/07/24/goldman-sachs-sees-big-gains-from-7-biotech-pharma-conviction-buy-stocks/"}, {"symbol": "VRTX", "publishedDate": "2020-07-20 09:00:00", "title": "Positive Phase 3 Study Results for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation", "image": "https://cdn.snapi.dev/images/v1/z/l/press20.jpg", "site": "Business Wire", "text": "BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of a global Phase 3 study of TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis (CF) ages 12 years and older who have one copy of the F508del mutation and one gating mutation (F/G) or one copy of the F508del mutation and one residual function mutation (F/RF). The study met its primary endpoint of mean absolute within-group change in percent predicted forced", "url": "https://www.businesswire.com/news/home/20200720005395/en/Positive-Phase-3-Study-Results-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor/"}, {"symbol": "VRTX", "publishedDate": "2020-07-20 07:04:44", "title": "Tax software company Vertex to offer 21.2 million shares in planned IPO, priced at $14 to $16 each", "image": "https://cdn.snapi.dev/images/v1/s/3/biotech22.jpg", "site": "Market Watch", "text": "Vertex Inc. VERX, set terms for its initial public offering on Monday, with plans to offer 21.2 million shares priced at $14 to $16 each.", "url": "https://www.marketwatch.com/story/tax-software-company-vertex-to-offer-212-million-shares-in-planned-ipo-priced-at-14-to-16-each-2020-07-20"}, {"symbol": "VRTX", "publishedDate": "2020-07-17 07:02:00", "title": "Better Buy: Vertex Pharmaceuticals vs. Regeneron", "image": "https://cdn.snapi.dev/images/v1/q/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5820592ffemale-scientist-holding-2-test-tubesjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Which stock wins in a battle of two big biotechs?", "url": "https://www.fool.com/investing/2020/07/17/better-buy-vertex-pharmaceuticals-vs-regeneron.aspx"}, {"symbol": "VRTX", "publishedDate": "2020-07-16 13:47:00", "title": "Vertex Pharmaceuticals Selects TRIA to Design Laboratory and Office for New 268,000 SF VCGT Research Site", "image": "https://cdn.snapi.dev/images/v1/l/m/press13.jpg", "site": "PRNewsWire", "text": "BOSTON, July 16, 2020 /PRNewswire/ -- TRIA, a principal-led architecture firm with a focus on designing unique workspaces for science, technology, and corporate clients, announced today that it is designing a new cell and genetic therapies research site in the Boston area for Vertex.", "url": "https://www.prnewswire.com/news-releases/vertex-pharmaceuticals-selects-tria-to-design-laboratory-and-office-for-new-268-000-sf-vcgt-research-site-301095035.html"}, {"symbol": "VRTX", "publishedDate": "2020-07-16 09:00:00", "title": "Vertex to Announce Second-Quarter 2020 Financial Results on July 30", "image": "https://cdn.snapi.dev/images/v1/k/z/conf12-2.jpg", "site": "Business Wire", "text": "BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2020 financial results on Thursday, July 30, 2020 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m.", "url": "https://www.businesswire.com/news/home/20200716005153/en/Vertex-Announce-Second-Quarter-2020-Financial-Results-July/"}, {"symbol": "VRTX", "publishedDate": "2020-07-15 17:45:21", "title": "Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/j/q/biotech5-2.jpg", "site": "Zacks Investment Research", "text": "Vertex Pharmaceuticals (VRTX) closed at $295.11 in the latest trading session, marking a +0.44% move from the prior day.", "url": "https://www.zacks.com/stock/news/1006001/vertex-pharmaceuticals-vrtx-gains-but-lags-market-what-you-should-know"}, {"symbol": "VRTX", "publishedDate": "2020-07-12 06:42:00", "title": "3 Absolutely Rock-Solid Stocks to Buy Before the Market Crashes Again", "image": "https://cdn.snapi.dev/images/v1/x/s/etf44-7.jpg", "site": "The Motley Fool", "text": "Be prepared for the next market downturn with these great stocks.", "url": "https://www.fool.com/investing/2020/07/12/3-absolutely-rock-solid-stocks-to-buy-before-the-m.aspx"}, {"symbol": "VRTX", "publishedDate": "2020-07-10 10:00:46", "title": "Why Biotechs Are Moving Up Among 4 Top-Rated Health Care Stocks", "image": "https://cdn.snapi.dev/images/v1/s/o/biotech23.jpg", "site": "Investors Business Daily", "text": "The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.", "url": "https://www.investors.com/news/technology/health-care-stocks-buy-watch/"}, {"symbol": "VRTX", "publishedDate": "2020-07-09 17:45:18", "title": "Vertex Pharmaceuticals (VRTX) Stock Moves -0.18%: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/m/f/biotech14.jpg", "site": "Zacks Investment Research", "text": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.40, moving -0.18% from the previous trading session.", "url": "https://www.zacks.com/stock/news/1001259/vertex-pharmaceuticals-vrtx-stock-moves-018-what-you-should-know"}, {"symbol": "VRTX", "publishedDate": "2020-07-07 17:48:02", "title": "5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm", "image": "https://cdn.snapi.dev/images/v1/s/d/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5697512fgloved-hands-holding-2-test-tubesjpgw700opresize.jpg", "site": "GuruFocus", "text": "In light of Novavax Inc. (NASDAQ:NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital.", "url": "https://www.gurufocus.com/news/1180274/5-greenblatt-magic-formula-biotech-stocks-to-weather-the-summer-coronavirus-storm"}, {"symbol": "VRTX", "publishedDate": "2020-07-07 17:40:19", "title": "They Can\u2019t Go Up Every Day; Stocks Fade After Strong Start", "image": "https://cdn.snapi.dev/images/v1/c/w/asset-management17-43.jpg", "site": "Investors Business Daily", "text": "Though the general market indexes faded by the close, a few breakouts are still worth mentioning.", "url": "https://www.youtube.com/watch?v=katajhpklo8"}, {"symbol": "VRTX", "publishedDate": "2020-07-07 10:00:28", "title": "These 3 Biotech Stocks Are Outperforming Their Peers \u2014 Here's Why", "image": "https://cdn.snapi.dev/images/v1/w/g/754485-stockmarket-istock-111524.jpg", "site": "Investors Business Daily", "text": "The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.\r\nThe post These 3 Biotech Stocks Are Outperforming Their Peers \u2014 Here's Why appeared first on Investor's Business Daily.", "url": "https://www.investors.com/news/technology/biotech-stocks-best-biotech-companies-to-invest-in/"}, {"symbol": "VRTX", "publishedDate": "2020-07-03 12:34:55", "title": "5 Booming Biotech Stocks to Buy", "image": "https://cdn.snapi.dev/images/v1/3/h/biotech-stocks-to-buy-0720.jpg", "site": "Kiplinger", "text": "These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.", "url": "https://www.kiplinger.com/investing/stocks/601016/booming-biotech-stocks-to-buy"}, {"symbol": "VRTX", "publishedDate": "2020-07-03 08:00:51", "title": "Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones", "image": "https://cdn.snapi.dev/images/v1/x/m/medical7.jpg", "site": "Investors Business Daily", "text": "Teladoc Health, Dexcom, Vertex Pharmaceuticals, Seattle Genetics and West Pharmaceutical Services are medical stocks in or near buy zones.\r\nThe post Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones appeared first on Investor's Business Daily.", "url": "https://www.investors.com/news/medical-stocks-teladoc-dexcom-vertex-seattle-genetics-near-buy-points/"}, {"symbol": "VRTX", "publishedDate": "2020-07-02 10:38:00", "title": "Better Buy: Vertex Pharmaceuticals vs. Galapagos", "image": "https://cdn.snapi.dev/images/v1/9/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5779842fgettyimages-506712062jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?", "url": "https://www.fool.com/investing/2020/07/02/better-buy-vertex-pharmaceuticals-vs-galapagos.aspx"}]